Compare Neurocrine Biosciences Inc (NBIX) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nutanix Inc — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Nutanix Inc trades at $54 (market cap $14.90B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Nutanix Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | NTNX | |
|---|---|---|
Market Cap | $17.40B | $14.90B |
Sector | Health | Technology |
52-Week High | $180.55 | $81.12 |
52-Week Low | $123.10 | $34.41 |
Enterprise Value | $16.49B | $14.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Nutanix (NTNX) trades at $55.11, up slightly by 0.05% today, with a bullish technical trend and strong analyst support. The company reported consistent earnings beats in recent quarters, with Q1 2026 EPS of $0.47 exceeding expectations. Revenue growth is projected to rise from $2.54 billion in 2025 to $2.7 billion in 2026, while net income margin improves to 10.03%. Recent news highlights partnerships and NVIDIA certification for its storage solutions, reinforcing its hybrid cloud positioning.
The outlook for NTNX is positive, driven by earnings momentum and strategic initiatives in AI infrastructure. Investment opportunities include potential upside to the $57.80 consensus price target and expanding profit margins. Key risks involve competitive pressures in cloud computing and reliance on enterprise spending cycles, which could impact growth if macroeconomic conditions weaken.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
